Uniphore Accelerates Expansion Across Europe

PALO ALTO, Calif. & LONDON--(BUSINESS WIRE)-- Uniphore, the Business AI Company, today announced a significant expansion across Europe, accelerating its commitment to the region through new customer adoption, partner momentum, product launches, and organizational investment.
'As we continue to evolve our customer data strategy, we're excited to see how Uniphore's Marketing Agents and complete AI platform will help us better engage audiences, streamline workflows, and drive more impactful marketing outcomes.'
The announcement coincides with the release of the Uniphore Business AI Cloud, announced during the AI Leadership Summit held yesterday in London—an exclusive gathering of media, industry leaders, and Uniphore customers exploring the future of agentic AI in Europe. Attendees included executives from ResultsCX, Konecta, KPMG, and Rowan Curran, Principal Analyst at Forrester, who shared perspectives on how enterprises are scaling AI from isolated pilots to business-critical systems that drive measurable outcomes across customer experience, marketing, operations and more.
A Platform Built for Europe's AI Mandate
As enterprise adoption of AI accelerates across Europe, CIOs and Line of Business Leaders face growing pressure to deliver solutions that align with the EU's AI Act. Uniphore's Business AI Cloud delivers on these requirements through a sovereign, composable, and secure platform that allows enterprises to activate AI across voice, video, text, structured and unstructured data — without compromising privacy or control.
With generative AI projected to grow at 55 percent annually in Europe and AI spending expected to exceed $133 billion in the region by 2028, European CIOs are under pressure to move beyond experimentation and deliver business-ready AI that is secure, compliant and operational at scale. Uniphore's Business AI Cloud is built to meet this demand, supporting the CIO mandate to operationalize AI across workflows while meeting strict data governance, privacy and ethical standards defined in the EU AI Act and other regulatory frameworks.
Fall 2025: Uniphore Marketing AI CDP Launches in EMEA
Uniphore will formally launch its Marketing AI CDP and Marketing Agents, part of the Business AI Suite, in the European market this fall. Built for enterprise marketers navigating complex privacy landscapes and fragmented customer data, the solution helps teams activate insights and deploy agentic marketing workflows — without requiring data movement or custom engineering.
Among Uniphore's newest customers in the region is Hearst UK, a leading media organization embracing AI to drive marketing automation and personalized engagement.
'We've been really pleased with the flexibility and composability of the Uniphore CDP,' said Krishan Gandhi, Senior Director of Data Engineering & Analytics at Hearst UK. 'As we continue to evolve our customer data strategy, we're excited to see how Uniphore's Marketing Agents and complete AI platform will help us better engage audiences, streamline workflows, and drive more impactful marketing outcomes.'
The Uniphore Business AI Suite includes Marketing AI, a CDP with pre-built agents purpose-built for enterprise marketers, including the Product Knowledge Agent (now generally available), which answers user questions in real time using indexed product documentation; the Platform Search Agent, launching in Summer 2025, which enables semantic search across audiences, attributes, and platform components; and the Audience Segmentation Agent, also arriving this summer, which allows marketers to build audience cohorts from plain-English prompts using both rule- and outcome-based logic. Together, these agents help enterprises accelerate first-party data activation while meeting GDPR compliance requirements out of the box.
Momentum with Konecta Drives Scaled Transformation
Uniphore also continues to deepen its relationship with global BPO leader Konecta, following the strategic partnership announced in late 2023. The companies are jointly scaling AI-led contact center transformation across Europe — automating quality monitoring, enabling real-time agent guidance and delivering measurable outcomes for telecom and financial services leaders.
'With Uniphore, we're building an agentic AI factory, designed to rapidly create, deploy and orchestrate AI agents across our customer environments,' said Oscar Vergé, chief AI deployment officer at Konecta. 'The platform's agent builder, orchestration engine and support for both prebuilt and custom agents allow us to agentify critical workflows for each client, from customer service to back-office automation. This isn't just AI adoption — it's real transformation at enterprise scale.'
Konecta leaders joined Uniphore onstage at the AI Leadership Summit in London to discuss deployment momentum and share learnings on production-grade enterprise AI.
Growing the Team and Leadership Across EMEA
Uniphore has significantly grown its presence in the region, expanding its team across sales, engineering, and customer success. The company now operates from a dedicated London office as well as an office in Valencia, Spain and is actively engaged in deployments across key markets throughout EMEA.
To support this growth, Jeremy Keefe has joined as Vice President of Sales, EMEA, bringing decades of enterprise software leadership to Uniphore's regional go-to-market strategy.
About Uniphore
Uniphore is the Business AI company. Our sovereign, composable, and secure AI platform connects enterprise data, fine-tunes AI models and deploys agentic AI across the enterprise. We empower every worker to boost productivity and help businesses grow faster, operate smarter and reduce costs. Trusted by more than 1,500 businesses globally, and recognized on the Deloitte Fast 500, Uniphore delivers on the promise of AI as a transformative force for business.
Learn more about Uniphore's Business AI Cloud and enterprise AI solutions at www.uniphore.com. For insights, updates and thought leadership, explore our blog or follow us on LinkedIn.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hamilton Spectator

2 hours ago

• Hamilton Spectator

Canada-Europe security and defence pact to be signed Monday in Brussels

OTTAWA - A security and defence partnership pact Prime Minister Mark Carney will sign with European leaders in Brussels on Monday will be among the most wide-ranging agreements with a third country Europe has ever reached, a senior EU official said on Friday. Carney is flying to Europe Sunday for a Canada — EU Summit, planned for Monday evening with European Council President António Costa and European Commission President Ursula von der Leyen. At the G7 summit in Alberta on Monday von der Leyen confirmed that the agreement will be signed on Monday in Brussels, calling Canada a 'key partner.' 'This is also a moment where we can strengthen Canada's role in Europe's rapidly evolving defence architecture,' said Von der Leyen on June 16. In a briefing to Canadian and European reporters on Friday, a senior European official said there will be two main outcomes from the summit — a joint statement that expresses views on global issues, such as conflicts in Ukraine and the Middle East, as well as the signing of the 'EU Canada Security and Defence Partnership Agreement.' 'This is an ambitious one,' the official said. 'And actually we've had this with a number of global partners, but the one with Canada would be one of the most far reaching of its kind that the EU has ever signed with a third country. It will open up new avenues for joint work on crisis management, military mobility, maritime security, cyber and cyber threats, and defence industrial co-operation.' Carney has been clear that he intends to expand Canada's ties with Europe as its relationship with the United States strains under the weight of tariffs and threats of annexation. Within two days of being sworn in as prime minister in March Carney flew to Europe, meeting with French President Emmanuel Macron in Paris and British Prime Minister Keir Starmer in London. It was during those meetings that he seriously began talking about signing on to Europe's new defence procurement plan known as ReArm Europe. In the throne speech on May 27, Carney's government pledged to join that program, and he told the CBC in an interview that same day he expected Canada to do that by July 1. On June 9, Carney announced a massive investment in Canada's defence budget to push Canada above the two per cent of GDP NATO target this country has promised — and failed — to meet for more than a decade. Joining ReArm Europe is part of that plan, with Carney repeatedly saying Canada can no longer put all its defence spending into the U.S. 'We are in close discussions with our European partners to join ReArm Europe,' he said on June 9. 'That will be an element of diversification. That's just smart. It's better to be diversified. It's better to have options. It's better to have different supply chains and broader partners.' The agenda for the summit posted by the European Council says the security and defence procurement agreement will allow Canada to join a European loan program for joint defence projects. That 150-billion euro program — called Security Action for Europe, or SAFE — is part of the ReArm Europe initiative. The EU official said on Friday that once the procurement agreement is in place, Canada will have to negotiate a bilateral agreement with the European Commission to begin discussions with member states about procurement opportunities. Leaders at the EU-Canada summit are also expected to discuss global trade and the wars raging in Ukraine and the Middle East. They will also commit to fully ratifying the Comprehensive Economic and Trade Agreement, the Canada-Europe free trade agreement known as CETA. Fen Hampson, a professor of international affairs at Carleton University, said Carney also should put the 'pedal to the metal' on ratifying CETA. The deal entered into force provisionally in 2017, but several EU member states still need to ratify CETA at the national level. 'The real challenge there is to get Canadian businesses and also European businesses to take it up … and to start doing more business across the Atlantic, but that also requires political leadership,' Hampson said. 'It hasn't been fully ratified but that's something (Carney) can perhaps impress upon the Europeans.' After Brussels, Carney will travel to The Hague for the NATO leaders' summit, where discussions are expected to push forward on increasing the NATO members' defence spending target as high as five per cent of GDP, from the current two per cent. — With files from Kyle Duggan, Dylan Robertson and The Associated Press This report by The Canadian Press was first published June 20, 2025. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

Yahoo

8 hours ago

• Yahoo

Trump wants one thing from the NATO summit. Europe is going to give it to him.

President Donald Trump wants one big thing from next week's NATO leader's summit — and European leaders are itching to give it to him. That doesn't guarantee the president will be satisfied. The 32-nation transatlantic military alliance will pledge to dramatically increase spending on defense to 5 percent of gross domestic product — 3.5 percent on hard military expenditures and 1.5 percent on more loosely defined defense-related efforts. The commitment, a watershed moment that could rebalance transatlantic security, will allow Trump, who's been demanding Europe pick up more of the burden for its own defense, a significant victory on the world stage. 'There is no way they would be going to 5 percent without Trump,' said one administration official, who was granted anonymity to share the president's views. 'So he sees this as a major win, and it is.' Trump intends to deliver a speech Wednesday at the summit's conclusion heralding the new spending pledge and his own catalytic role. But Trump's victory won't prevent him from pressuring countries to do even more, faster, which could prove difficult for some in the alliance. Spain, the NATO member with the lowest defense spending rate, isasking for an exemption from the new pledge and there is broad disagreement over the date by which this spending pledge is to be met. 'They're thinking of a timeline that is, frankly, a decade,' said Ivo Daalder, a former U.S. ambassador to NATO under President Barack Obama. 'Trump is probably thinking of a timeline that is by the end of this decade, if not sooner. That's where I think [the summit] can blow up.' While NATO allies are at odds over the details of the security pledge, there is broad agreement about the overriding importance of keeping Trump happy and maintaining a united front in The Hague, with Russia's war in Ukraine nowhere near an end and America's foreign policy focus increasingly shifting to Asia and the Middle East. In service of that aim, summit organizers have streamlined the meeting, reducing what is typically a two-day affair to 24 hours and focusing it around Trump's pledge, which has been negotiated ahead of time, and almost nothing else. 'He has to get credit for the 5 percent — that's why we're having the summit,' said one European defense official, granted anonymity to speak candidly about private government-level conversations. 'Everything else is being streamlined to minimize risk.' Asked about the pledge on Friday, Trump expressed support for allies spending more but added the 5 percent target shouldn't apply to the U.S., which is at 3.4 percent. Trump's saber-rattling toward Iran,teasing the possibility that the U.S. would join Israel's military campaign to destroy the country's nuclear development infrastructure and potentially topple the regime, has injected new uncertainty into a summit NATO officials had hoped to tightly script. But as of Friday, there were no formal plans to meet with allies to discuss the situation in the Middle East, though it could provide an opportunity for the president to tout the need for increased defense spending. NATO officials decided to pare down the agenda before Trump abruptly left the G7 halfway through the two-day program, a move that the administration official later attributed largely to his impatience with largely ceremonial multilateral meetings. In The Hague, as was the case in Canada, there will be no lengthy communique, only short statements about new commitments. The shortened NATO schedule allows for only two main events: a welcome dinner at the Dutch royal family's castle and a single meeting of the North Atlantic Council rather than the usual two or three, according to five people familiar with the planning. It is not clear if Ukrainian President Volodymyr Zelenskyy, invited only to the summit's opening dinner on Tuesday, will attend. And there won't be a meeting of NATO's Ukraine council in The Hague. It's another concession to the U.S., which, despite the urging of some allies to hold such a session, wasn't interested in heightening the focus on the war that Trump has been unable to resolve as he promised during last year's campaign. Paring down the summit is also a way for NATO allies to gloss over the persistent divide among countries about a critical detail of their pledge: how soon they'll be expected to reach the new spending benchmark. While the U.S. — and countries in eastern Europe already above the 3.5 percent benchmark — prefer a deadline of 2030, smaller countries, struggling to reach the new goals, want until 2032 or 2035. NATO Secretary General Mark Rutte floated 2032 as a compromise but, amid pushback from several smaller countries in recent days, the final wording of the pledge could give countries until 2035 to hit 5 percent, according to a European official familiar with private negotiations. 'For a lot of countries, this is the whole issue,' the European defense official continued. 'It's not so difficult to say, 'Yes, we will, we will agree.' But it's very difficult to find the right path and to actually find the budget for that path. So that's why nobody, nobody wants to talk about it anymore.' It's possible that the matter of the timeline won't be resolved during the summit. 'The priority is really to announce success in The Hague,' said another European official, also granted anonymity because they were not authorized to speak publicly. 'The longer-term perspective is less important.' NATO officials and European allies are determined to avoid a repeat of the 2018 summit in Brussels, which Trump upended by threatening to withdraw the U.S. from the alliance altogether if other countries didn't get serious about reaching the 2 percent spending benchmark they'd agreed to four years earlier. More than anything since, Russia's invasion of Ukraine in February 2022 altered defense calculations for Europe, pushing several countries to meet the 2 percent threshold and prompting Sweden and Finland, after decades of neutrality, to join the alliance. With the war ongoing and Trump back in office, the increased spending commitments are at least as much about Europe's long-term defense as they are appeasing the unpredictable Trump. In his speech this week at London's Chatham House, Rutte began to publicly lay out NATO's new capability targets — the amount of military equipment needed to implement a defense plan against a potential Russian attack — that defense ministers agreed to earlier this month. The alliance, Rutte said, needs 'a 400 percent increase in air and missile defence … thousands more armored vehicles and tanks, millions more artillery shells, and we must double our enabling capabilities, such as logistics, supply, transportation, and medical support.' Over time, that will lead to Europe carrying more of the burden for its own defense — and having more sway within the alliance. 'You now have a road map for Europeanizing NATO that you never had before, and that ultimately will lead to a more successful alliance,' Daalder said. 'Everybody wants to move in that direction, the U.S. and the Europeans.' Trump has long groused that the U.S. shoulders too much of the cost for defending the world and has pushed more than just NATO members to increase their defense budgets. The administration is also pressuring Japan, a non-NATO ally pursuing a new trade deal with Washington, to boost its defense spending significantly with the Pentagon describing the 5 percent benchmark as a new 'global standard.' It's a standard many countries may struggle to reach. Spain, far from the alliance's eastern flank, has been difficult to convince, as have other smaller countries such as Italy and Belgium that are still not hitting the 2 percent level the alliance adopted in 2014. Even Great Britain, one of Europe's biggest military powers, has balked at the 2032 deadline. Laying out a plan for boosting defense spending, Prime Minister Keir Starmer promised the U.K. would be at 2.5 percent by 2027 and expressed confidence about getting to 3 percent by 2034, at the latest. Paul McLeary contributed to this report.

Business Wire

8 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.